Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $23.67.
A number of equities research analysts have recently commented on SLRN shares. Wells Fargo & Company raised their price objective on shares of Acelyrin from $11.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 21st. HC Wainwright reaffirmed a "buy" rating and set a $28.00 price objective on shares of Acelyrin in a research note on Monday, April 1st.
View Our Latest Stock Report on Acelyrin
Acelyrin Stock Down 6.8 %
Shares of NASDAQ SLRN traded down $0.39 during midday trading on Friday, reaching $5.37. 489,507 shares of the stock were exchanged, compared to its average volume of 1,542,266. The firm has a market cap of $528.19 million and a price-to-earnings ratio of -0.51. Acelyrin has a twelve month low of $5.34 and a twelve month high of $29.88. The firm has a 50-day simple moving average of $7.48 and a two-hundred day simple moving average of $7.94.
Insider Activity at Acelyrin
In related news, CEO Shao-Lee Lin sold 15,701 shares of Acelyrin stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $7.60, for a total value of $119,327.60. Following the sale, the chief executive officer now owns 1,587,335 shares of the company's stock, valued at approximately $12,063,746. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Institutional Investors Weigh In On Acelyrin
A number of institutional investors have recently added to or reduced their stakes in SLRN. Bank of New York Mellon Corp purchased a new position in Acelyrin in the 2nd quarter valued at $276,000. Charles Schwab Investment Management Inc. purchased a new position in Acelyrin in the 2nd quarter valued at $3,328,000. Osaic Holdings Inc. purchased a new position in Acelyrin in the 2nd quarter valued at $25,000. Northern Trust Corp purchased a new position in Acelyrin in the 2nd quarter valued at $1,215,000. Finally, Geode Capital Management LLC purchased a new position in Acelyrin in the 2nd quarter valued at $7,268,000. Institutional investors and hedge funds own 87.31% of the company's stock.
Acelyrin Company Profile
(
Get Free ReportAcelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Featured Articles
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
